Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
3 Magnificent Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 8.5% -- to Buy With Confidence in November
These supercharged income stocks have the necessary catalysts to pad the pocketbooks of patient investors. 
Via The Motley Fool
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins. 
Via Stocktwits
Topics Lawsuit
PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year... 
Via StockStory
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Earnings Scheduled For November 4, 2025
 
Via Benzinga
U.S. PMI Data Looms: A Pivotal Moment for the Dollar and Global Markets
The financial world is holding its breath as the release of the upcoming U.S. Purchasing Managers' Index (PMI) data draws near. This crucial economic indicator is not merely a snapshot of business... 
Via MarketMinute
Topics Bonds Economy Supply Chain
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
Precious Metals Under Pressure: Dollar Rallies, Stocks Retreat, and Rate Outlook Weighs Heavily
As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and... 
Via MarketMinute
Topics Economy Stocks Supply Chain
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk. 
Via Benzinga
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. 
Via Benzinga
Curious about the most active S&P500 stocks in today's session?
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Most active stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. 
Via Chartmill
Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs. 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session. 
Via Chartmill
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday?
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date... 
Via Benzinga
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Pfizer (PFE) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid. 
Via Investor's Business Daily
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates
 
Via Benzinga
Topics Stocks
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. 
Via Stocktwits
Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs
Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales. 
Via Benzinga
Pfizer’s (NYSE:PFE) Q3 Earnings Results: Revenue In Line With Expectations
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year... 
Via StockStory
Pfizer Raises Profit Outlook Even As Third-Quarter Sales Decline
Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view. 
Via Investor's Business Daily
Is Eli Lilly a Millionaire Maker?
Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider. 
Via The Motley Fool
Topics Intellectual Property
Zoetis (NYSE:ZTS) Reports Q3 In Line With Expectations But Stock Drops
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance... 
Via StockStory
Pfizer Inc (NYSE:PFE) Reports Q3 2025 Earnings Beat and Raises Full-Year Profit Guidance
Pfizer Q3 2025 earnings beat estimates and the company raised its full-year profit guidance, highlighting strong cost management and non-COVID portfolio growth. 
Via Chartmill
Topics Earnings
Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates
The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 
Via Stocktwits
Topics Artificial Intelligence World Trade
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
From Pfizer Inc.
Via Business Wire
Pfizer Tops EPS Expectations In Q3 2025 Despite Revenue Decline
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise. 
Via Talk Markets
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies. 
Via The Motley Fool
Topics Energy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.